Integrated PET/CT and cancer imaging

JBR-BTR

Volumn 92, Issue 1, 2009, Pages 13-19

  De Wever, W ^a,b   Coolen, J ^a   Verschakelen, J A ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Emission CT (ECT)

Indexed keywords

ARTICLE; BREAST CANCER; BREATHING PATTERN; CANCER STAGING; CLINICAL PRACTICE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; ESOPHAGUS CANCER; HEAD AND NECK CANCER; HUMAN; IMAGE QUALITY; LUNG CANCER; MELANOMA; PLEURA EFFUSION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RADIATION DEPTH DOSE; RADIATION DOSE; TREATMENT PLANNING;

CONTRAST MEDIA; HUMANS; NEOPLASM STAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOGRAPHIC IMAGE ENHANCEMENT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 63849203944     PISSN: 17802393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Cerfolio R.J., Ojha B., Bryant A.S., Raghuveer V., Mountz J.M., Bartolucci A.A.: The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg, 2004, 78: 1017- 1023; discussion 1017-1023.
2. Lardinois D., Weder W., Hany T.F., Kamel E.M., Korom S., Seifert B., von Schulthess G.K., Steinert H.C.: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med, 2003, 348: 2500- 2507.
3. Antoch G., Stattaus J., Nemat A.T., Marnitz S., Beyer T., Kuehl H., Bockisch A., Debatin J.F., Freudenberg L.S.: Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology, 2003, 229: 526-533.
4. Correia J.A.: Registration of nuclear medicine images. J Nucl Med, 1990, 31:1227-1229.
5. Wahl R.L., Quint L.E., Greenough R.L., Meyer C.R., White R.I., Orringer M.B.: Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology, 1994, 191: 371-377.
6. Bar-Shalom R., Yefremov N., Guralnik L, Gaitini D., Frenkel A., Kuten A., Altman H., Keidar Z., Israel O.: Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med, 2003, 44: 1200-1209.
7. Hany T.F., Steinert H.C., Goerres G.W., Buck A., von Schulthess G.K.: PET diagnostic accuracy: improvement with in-line PET-CT system: initial results. Radiology, 2002, 225: 575- 581.
8. Pfannenberg A.C., Aschoff P., Brechtel K., Muller M., Bares R., Paulsen F., Scheiderbauer J., Friedel G., Claussen C.D., Eschmann S.M.: Low dose nonenhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer. Eur J Nucl Med Mol Imaging, 2007, 34: 36-44.
9. Goerres G.W., Kamel E., Heidelberg T.N., Schwitter M.R., Burger C, von Schulthess G.K.: PET- CT image co-registration in the thorax: influence of respiration. Eur J Nucl Med Mol Imaging, 2002, 29: 351- 360.
10. Beyer T., Antoch G., Blodgett T., Freudenberg L.F., Akhurst T., Mueller S.: Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging, 2003, 30: 588-596.
11. de Juan R., Seifert B., BertholdT, von Schulthess G.K., Goerres G.W.: Clinical evaluation of a breathing protocol for PET/CT. Eur Radiol, 2004, 14: 1118-1123.
12. Antoch G., Freudenberg L.S., Beyer T., Bockisch A., Debatin J.F.:To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F- FDG PET/CT. J Nucl Med, 2004, 45 Suppl 1: 56S-65S.
13. Yau Y.Y., Chan W.S., Tarn Y.M., Vernon R,Wong S., Coel M., Chu S.K.: Application of intravenous contrast in PET/CT: does it really introduce significant attenuation correction error? J Nucl Med, 2005, 46: 283-291.
14. Cohade C., Osman M., Nakamoto Y., Marshall L.T., Links J.M., Fishman E.K., Wahl R.L.: Initial experience with oral contrast in PET/CT: phantom and clinical studies. J Nucl Med, 2003, 44: 412-416.
15. Antoch G., Freudenberg L.S., Stattaus J., Jentzen W., Mueller S.R, Debatin J.F., Bockisch A.: Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol, 2002, 179: 1555-1560.
16. Siegel B.A., Dehdashti F.: Oncologic PET/CT: current status and controversies. Eur Radiol, 2005, 15 Suppl 4: D127-132.
17. Reinartz P., Wieres F.J., Schneider W., Schur A., Buell U.: Side-by-side reading of PET and CT scans in oncology: which patients might profit from integrated PET/CT? Eur J Nucl Med Mol Imaging, 2004, 31: 1456-1461.
18. Collins C.D.: PET/CT in oncology: for which tumours is it the reference standard? Cancer Imaging, 2007, 7 Spec No A: S77-87.
19. lagaru A., Masamed R., Keesara S., Conti P.S.: Breast MRI and 18F FDG PET/CT in the management of breast cancer. Ann Nucl Med, 2007, 21: 33- 38.
20. Radan L., Ben-Haim S., Bar- Shalom R., Guralnik L., Israel 0.:The role of FDG-PET/CT in suspected recurrence of breast cancer. Cancer, 2006, 107: 2545-2551.
21. Francis D.L., Visvikis D., Costa D.C., Arulampalam T.H., Townsend C, Luthra S.K.,Taylor I., Ell P.J.: Potential impact of (18F)3'-deoxy-3'- fluorothymidine versus (18F)fluoro-2- deoxy-D-glucose in positron emission tomography for colorectal cancer. Eur J Nucl Med Mol Imaging, 2003, 30: 988-994.
22. Selzner M., Hany T.F., Wildbrett P., McCormack L., Kadry Z., Clavien PA.: Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg, 2004, 240: 1027-1034; discussion 1035-1026.
23. Cohade C., Osman M., Leal J., Wahl R.L.: Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med, 2003, 44: 1797-1803.
24. Even-Sapir E., Parag Y., Lerman H., Gutman M., Levine C., Rabau M., Figer A., Metser U.: Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology, 2004,232:815-822.
25. Kim J.H., Czernin J., Allen- Auerbach M.S., Halpern B.S., Fueger B.J., Hecht J.R., Ratib O., Phelps M.E., Weber W.A.: Comparison between 18F-FDG PET, in-line PET/CT, and software fusion for restaging of recurrent colorectal cancer. J Nucl Med, 2005, 46: 587-595.
26. Freudenberg L.S., Fischer M., Antoch G., Jentzen W., Gutzeit A., Rosenbaum S.J., Bockisch A., Egelhof T: Dual modality of 18F-fluorodeoxyglucose- positron emission tomography/computed tomography in patients with cervical carcinoma of unknown primary. Med Princ Pract, 2005, 14: 155-160.
27. Branstetter B.F., Blodgett T.M., Zimmer L.A., Snyderman C.H., Johnson J.T., Raman S., Meltzer C.C.: Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology, 2005, 235: 580-586.
28. Rodel R., Straehler-Pohl H.J., Palmedo H., Reichmann K., Jaeger U., Reinhardt M.J., Biersack H.J.: (PET/CT imaging in head and neck tumors). Radiologe, 2004, 44: 1055-1059.
29. Schoder H., Yeung H.W., Gonen M., Kraus D., Larson S.M.: Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology, 2004, 231: 65-72.
30. Zanation A.M., Sutton D.K., Couch M.E., Weissler M.C., Shockley W.W., Shores C.G.: Use, accuracy, and implications for patient management of (18F)-2-fluorodeoxyglucose-positron emission/ computerized tomography for head and neck tumors. Laryngoscope, 2005, 115: 1186-1190.
31. Ciernik I.F., Dizendorf E., Baumert B.G., Reiner B., Burger C., Davis J.B., Lutolf U.M., Steinert H.C., Von Schulthess G.K.: Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys, 2003, 57: 853-863.
32. Koshy M., Paulino A.C., Howell R., Schuster D., Halkar R., Davis L.W.: F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck, 2005, 27: 494-502.
33. Paulino A.C., Koshy M., Howell R., Schuster D., Davis L.W.: Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys, 2005, 61: 1385-1392.
34. Halpern B.S., Schiepers C., Weber W.A., Crawford T.L., Fueger B.J., Phelps M.E., Czernin J.: Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest, 2005, 128: 2289-2297
35. Shim S.S., Lee K.S., Kim B.T., Chung M.J., Lee E.J., Han J., Choi J.Y., Kwon O.J., Shim Y.M., Kim S.: Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology, 2005, 236; 1011-1019.
36. De Wever W., Ceyssens S., Mortelmans L., Stroobants S., Marchal G., Bogaert J., Verschakelen J.A.: Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol, 2007, 17: 23-32.
37. Pauls S., Buck A.K., Hohl K., Halter G., Hetzel M., Blumstein N.M., Mottaghy F.M., Glatting G., Kruger S., Sunder-Plassmann L., Moller P., Hombach V., Brambs H.J., Reske S.N.: Improved non-invasive T-Staging in non-small cell lung cancer by integrated 18F-FDG PET/CT. Nuklearmedizin, 2007, 46: 9-14; quiz N11-12.
38. De Leyn P., Stroobants S., De Wever W., Lerut T, Coosemans W., Decker G., Nafteux P., Van Raemdonck D., Mortelmans L., Nackaerts K., Vansteenkiste J.: Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 Non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol, 2006, 24: 3333-3339.
39. De Wever W.: Role of integrated PET/CT in the staging of non-small lung cancer. Leuven: KULeuven, 2008.
40. DeWever W., Vankan Y, Stroobants S., Verschakelen J.: Detection of extrapulmonary lesions with integrated PET/CT in the staging of lung cancer. Eur Respir J, 2007, 29: 995-1002.
41. Schaefer N.G., Hany T.F., Taverna C., Seifert B., Stumpe K.D., von Schulthess G.K., Goerres G.W.: Non- Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging - do we need contrast-enhanced CT? Radiology, 2004, 232: 823-829.
42. Allen-Auerbach M., Quon A., Weber W.A., Obrzut S., Crawford T., Silverman D.H., Ratib O., Phelps M.E., Czernin J.: Comparison between 2-deoxy-2-[18F)fluoro-D-glucose positron emission tomography and positron emission tomography/computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol, 2004, 6: 411-416.
43. Freudenberg L.S., Antoch G., Schutt P., Beyer T., Jentzen W., Muller S.P., Gorges R., Nowrousian M.R., Bockisch A., Debatin J.F.: FDG- PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging, 2004, 31: 325-329.
44. Pfannenberg C., Aschoff P., Schanz S., Eschmann S.M., Plathow C., Eigentler T.K., Garbe C., Brechtel K., Vonthein R., Bares R., Claussen C.D., Schlemmer H.P.: Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer, 2007, 43: 557-564.
45. Mottaghy F.M., Sunderkotter C., Schubert R., Wohlfart P., Blumstein N.M., Neumaier B., Glatting G., Ozdemir C., Buck A.K., Scharffetter-Kochanek K., Reske S.N.: Direct comparison of (18F)FDG PET/CT with PET alone and with sideby-side PET and CT in patients with malignant melanoma. Eur J Nucl Med Mol Imaging, 2007, 34: 1355- 1364.
46. Bar-Shalom R., Guralnik L.,Tsalic M., Leiderman M., Frenkel A., Gaitini D., Ben-Nun A., Keidar Z., Israel O.: The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging, 2005, 32: 918-924.
47. Cerfolio R.J., Bryant A.S., Ohja B., Bartolucci A.A., Eloubeidi M.A.: The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg, 2005, 129: 1232-1241.
48. van Tinteren H., Hoekstra O.S., Smit E.F., van den Bergh J.H., Schreurs A.J., Stallaert R.A., van Velthoven PC, Comans E.F., Diepenhorst F.W., Verboom P., van Mourik J.C., Postmus RE., Boers M., Teule G.J.: Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet, 2002, 359 (9315): 1388- 1393.
49. von Schulthess G.K.: Cost considerations regarding an integrated CT-PET system. Eur Radiol, 2000, 10 Suppl 3: S377-380.
50. Verboom P., van Tinteren H., Hoekstra O.S., Smit E.F., van den Bergh J.H., Schreurs A.J., Stallaert R.A., van Velthoven P.C., Comans E.F., Diepenhorst F.W., van Mourik J.C., Postmus P.E., Boers M., Grijseels E.W., Teule G.J., Uyl-de Groot C.A.: Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging, 2003, 30: 1444-1449.
51. Herder G.J., Kramer H., Hoekstra O.S., Smit E.F., Pruim J., van Tinteren H., Comans E.F., Verboom P., Uyl-de Groot C.A., Welling A., Paul M.A., Boers M., Postmus P.E., Teule G.J., Groen H.J.: Traditional versus up-front (18F) fluorodeoxyglucose-positron emission tomography staging of non-small-cell lung cancer: a Dutch cooperative randomized study. J Clin Oncol, 2006, 24: 1800- 1806.
52. Pretreatment evaluation of nonsmall-cell lung cancer. The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med, 1997, 156: 320-332.